

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LeDoux Anne M</u> <hr/> (Last) (First) (Middle) <u>C/O CORCEPT THERAPEUTICS</u> <u>149 COMMONWEALTH DRIVE</u> <hr/> (Street) <u>MENLO</u> <u>CA</u> <u>94025</u> <u>PARK</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/16/2007	3. Issuer Name and Ticker or Trading Symbol <u>CORCEPT THERAPEUTICS INC [CORT]</u> <hr/> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">VP & Controller</p>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	--	---	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	04/16/2014	Common Stock	17,500	12	D	
Stock Option (right to buy)	(2)	10/06/2014	Common Stock	42,500	7.73	D	
Stock option (right to buy)	(3)	09/23/2015	Common Stock	15,000	5.7	D	

Explanation of Responses:

1. Exercisable with respect to 20% of the total number of options shares one year after 4/16/2004 and with respect to an additional 1.67% of the total number of option shares on the monthly anniversary of 4/16/2004 each month thereafter.
2. Exercisable with respect to 20% of the total number of options shares one year after 10/6/2004 and with respect to an additional 1.67% of the total number of option shares on the monthly anniversary of 10/6/2004 each month thereafter.
3. Exercisable with respect to 20% of the total number of options shares one year after 9/23/2005 and with respect to an additional 1.67% of the total number of option shares on the monthly anniversary of 9/23/2005 each month thereafter.

Remarks:

/s/ Joseph K. Belanoff, CEO of
Corcept Therapeutics 04/18/2007
Incorporated, attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.